Breaking Down Theravance Biopharma: 5 Analysts Share Their Views
Throughout the last three months, 5 analysts have evaluated Theravance Biopharma (NASDAQ:TBPH), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 1 | 0 | 0 |
| 1M Ago | 3 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $23.4, a high estimate of $40.00, and a low estimate of $14.00. A 24.52% drop is evident in the current average compared to the previous average price target of $31.00.
Interpreting Analyst Ratings: A Closer Look
A comprehensive examination of how financial experts perceive Theravance Biopharma is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Douglas Tsao | HC Wainwright & Co. | Lowers | Buy | $15.00 | $27.00 |
| Mayank Mamtani | B. Riley Securities | Lowers | Neutral | $14.00 | $28.00 |
| Julian Harrison | BTIG | Lowers | Buy | $21.00 | $40.00 |
| Douglas Tsao | HC Wainwright & Co. | Raises | Buy | $27.00 | $20.00 |
| Julian Harrison | BTIG | Maintains | Buy | $40.00 | $40.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Theravance Biopharma. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Theravance Biopharma compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Theravance Biopharma's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Theravance Biopharma analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Get to Know Theravance Biopharma Better
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Understanding the Numbers: Theravance Biopharma's Finances
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining Theravance Biopharma's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 18.51% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Theravance Biopharma's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 18.08% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Theravance Biopharma's ROE excels beyond industry benchmarks, reaching 1.58%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Theravance Biopharma's ROA stands out, surpassing industry averages. With an impressive ROA of 0.86%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Theravance Biopharma's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.19.
The Basics of Analyst Ratings
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.